<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The TNF-family molecule, RANKL, is a key regulator of bone remodeling and essential for the development and activation of osteoclasis </plain></SENT>
<SENT sid="1" pm="."><plain>Bone involvement signals diesease activity in non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and influences the progenesis </plain></SENT>
<SENT sid="2" pm="."><plain>The molecular mechanism and soluble factors involved in osteoclastic activation in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> remain unclear except for <z:hpo ids='HP_0006775'>Multiple Myeloma</z:hpo> and Adult T-cell <z:hpo ids='HP_0001909'>Leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this paper is to report the first case of Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> with bone involvement displaying an aberrant expression of RANKL in malignant cells </plain></SENT>
<SENT sid="4" pm="."><plain>The detection of RANKL in Follicullar <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> may help to prevent <z:e sem="disease" ids="C0238792" disease_type="Disease or Syndrome" abbrv="">bone lesion</z:e> in patients by determining an appropriate treatment </plain></SENT>
</text></document>